These 2 Pharma Giants May Be on Pfizer's M&A Radar Right Now
Despite overcoming a whopping $23 billion in branded patent expirations over the course of 2011 to 2016 and returning to growth on an operational basis, Wall Street thinks Pfizer (NYSE: PFE) still has a lot more to work to do. The basic issue is that Pfizer is barreling toward another round of high-value patent expirations. The erectile-dysfunction medicine Viagra and top-selling pain drug Lyrica, for example, could both face generic competition in the United States by next year.
Compounding matters, sales of Pfizer's pneumococcal vaccine Prevnar 13 have been flattening in recent quarters, and the drugmaker's foray into the next-generation cholesterol market ended in disappointment after the company shuttered its bococizumab program last year.
As Pfizer's recent acquisitions of Anacor Pharmaceuticals, Hospira, and Medivation simply aren't enough to overcome these headwinds to maintain a respectable growth trajectory, analysts are once again clamoring for the drugmaker to revisit the idea of engaging in a so-called "megadeal."
Source: Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 31 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 57.33% compared to the current price of 26.06 € for Pfizer Inc..
